001     153984
005     20240227115125.0
024 7 _ |a 10.1126/scitranslmed.aaz3267
|2 doi
024 7 _ |a 1946-6234
|2 ISSN
024 7 _ |a 1946-6242
|2 ISSN
024 7 _ |a altmetric:83860729
|2 altmetric
024 7 _ |a pmid:32522805
|2 pmid
037 _ _ |a DZNE-2021-00001
082 _ _ |a 500
100 1 _ |a Lutz, Anne-Kathrin
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Autism-associated SHANK3 mutations impair maturation of neuromuscular junctions and striated muscles
260 _ _ |a Washington, DC
|c 2020
|b AAAS
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1708965254_5085
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Heterozygous mutations of the gene encoding the postsynaptic protein SHANK3 are associated with syndromic forms of autism spectrum disorders (ASDs). One of the earliest clinical symptoms in SHANK3-associated ASD is neonatal skeletal muscle hypotonia. This symptom can be critical for the early diagnosis of affected children; however, the mechanism mediating hypotonia in ASD is not completely understood. Here, we used a combination of patient-derived human induced pluripotent stem cells (hiPSCs), Shank3Δ11(−/−) mice, and Phelan-McDermid syndrome (PMDS) muscle biopsies from patients of different ages to analyze the role of SHANK3 on motor unit development. Our results suggest that the hypotonia in SHANK3 deficiency might be caused by dysfunctions in all elements of the voluntary motor system: motoneurons, neuromuscular junctions (NMJs), and striated muscles. We found that SHANK3 localizes in Z-discs in the skeletal muscle sarcomere and co-immunoprecipitates with α-ACTININ. SHANK3 deficiency lead to shortened Z-discs and severe impairment of acetylcholine receptor clustering in hiPSC-derived myotubes and in muscle from Shank3Δ11(−/−) mice and patients with PMDS, indicating a crucial role for SHANK3 in the maturation of NMJs and striated muscle. Functional motor defects in Shank3Δ11(−/−) mice could be rescued with the troponin activator Tirasemtiv that sensitizes muscle fibers to calcium. Our observations give insight into the function of SHANK3 besides the central nervous system and imply potential treatment strategies for SHANK3-associated ASD.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 1
536 _ _ |a POF III - Programmorientierte Förderung III (POF)
|0 G:(DE-HGF)POF3
|c POF
|x 2
536 _ _ |a DISPLAYGHT - DISPLAY backliGHT illumination by femtosecond laser micromachining (862085)
|0 G:(EU-Grant)862085
|c 862085
|f ERC-2019-PoC
|x 3
588 _ _ |a Dataset connected to DataCite
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Autistic Disorder
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Induced Pluripotent Stem Cells
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Microfilament Proteins
|2 MeSH
650 _ 2 |a Muscle, Skeletal
|2 MeSH
650 _ 2 |a Mutation: genetics
|2 MeSH
650 _ 2 |a Nerve Tissue Proteins: genetics
|2 MeSH
650 _ 2 |a Neuromuscular Junction
|2 MeSH
700 1 _ |a Pfaender, Stefanie
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Incearap, Berra
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Ioannidis, Valentin
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Ottonelli, Ilaria
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Föhr, Karl J.
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Cammerer, Judith
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Zoller, Marvin
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Higelin, Julia
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Giona, Federica
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Stetter, Maximilian
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Stoecker, Nicole
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Alami, Najwa Ouali
|0 P:(DE-2719)9001442
|b 12
|u dzne
700 1 _ |a Schön, Michael
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Orth, Michael
|0 P:(DE-2719)9001440
|b 14
|u dzne
700 1 _ |a Liebau, Stefan
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Barbi, Gotthold
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Grabrucker, Andreas M.
|0 P:(DE-HGF)0
|b 17
700 1 _ |a Delorme, Richard
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Fauler, Michael
|0 P:(DE-HGF)0
|b 19
700 1 _ |a Mayer, Benjamin
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Jesse, Sarah
|0 P:(DE-2719)9001441
|b 21
|u dzne
700 1 _ |a Roselli, Francesco
|0 P:(DE-2719)2812851
|b 22
700 1 _ |a Ludolph, Albert C.
|0 P:(DE-2719)2812633
|b 23
700 1 _ |a Bourgeron, Thomas
|0 0000-0001-8164-9220
|b 24
700 1 _ |a Verpelli, Chiara
|0 P:(DE-HGF)0
|b 25
700 1 _ |a Demestre, Maria
|0 0000-0002-3672-5703
|b 26
700 1 _ |a Böckers, Tobias
|0 P:(DE-2719)2812855
|b 27
|e Last author
773 _ _ |a 10.1126/scitranslmed.aaz3267
|g Vol. 12, no. 547, p. eaaz3267 -
|0 PERI:(DE-600)2518839-2
|n 547
|p eaaz3267 -
|t Science translational medicine
|v 12
|y 2020
|x 1946-6242
909 C O |o oai:pub.dzne.de:153984
|p openaire
|p VDB
|p ec_fundedresources
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)9001442
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)9001440
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)9001441
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)2812851
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 23
|6 P:(DE-2719)2812633
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)2812855
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
913 1 _ |a DE-HGF
|x 2
|3 G:(DE-HGF)POF3
|4 G:(DE-HGF)POF
913 2 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-30
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI TRANSL MED : 2021
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-16
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b SCI TRANSL MED : 2021
|d 2022-11-16
920 1 _ |0 I:(DE-2719)1910002
|k AG Böckers
|l Translational Protein Biochemistry
|x 0
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center Ulm
|l Clinical Study Center Ulm
|x 1
920 1 _ |0 I:(DE-2719)1910001
|k AG Roselli
|l Metabolic Changes in Neurodegeneration
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1910002
980 _ _ |a I:(DE-2719)5000077
980 _ _ |a I:(DE-2719)1910001
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21